Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Malone

Nurse Practitioner, Family Ashland, KY Nurse Practitioner

NPI 1134766991 CMS profile 10914333

613 23Rd St Ste G10, Ashland, KY 41101

Open in the dashboard

General payments

$13,626

737 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Malone of Ashland, KY is reported in the CMS Open Payments database as having received $13,626 across 737 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,676 205
2024 General $3,370 171
2023 General $2,667 131
2022 General $2,559 145
2021 General $1,355 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Malone
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Malone were reported at $3,676. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Malone Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,355 $124 $35–$379 $132
2022 $2,559 $141 $44–$430 $149
2023 $2,667 $154 $49–$476 $160
2024 $3,370 $165 $51–$504 $164
2025 $3,676 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $2,804 193 payments
  2. AstraZeneca Pharmaceuticals LP $1,932 92 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,133 57 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,017 57 payments
  5. Inspire Medical Systems, Inc. $661 27 payments
  6. Grifols USA, LLC $644 34 payments
  7. Mylan Specialty L.P. $612 28 payments
  8. Electromed, Inc. $602 41 payments
  9. Philips Electronics North America Corporation $578 23 payments
  10. Axsome Therapeutics, Inc. $572 28 payments
  11. Other $3,070 157 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,327 729 payments
  2. Education $300 8 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,905 131 payments
  2. FASENRA $1,106 40 payments
  3. NUCALA $858 58 payments
  4. GLASSIA $833 48 payments
  5. YUPELRI $773 35 payments
  6. BREZTRI $723 26 payments
  7. TEZSPIRE $683 23 payments
  8. INSPIRE $661 27 payments
  9. Prolastin-C Liquid $644 34 payments
  10. OFEV $599 30 payments
  11. Other $6,148 309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,870

Median for Nurse Practitioner: 389

Drug cost

$994,086

Median for Nurse Practitioner: $21,885

Branded share of claims

70.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 356 $346,780
Prolastin C Alpha-1-Proteinase Inhibitor Brand 13 $202,283
Nucala Mepolizumab Brand 23 $84,108
Fasenra Pen Benralizumab Brand 12 $66,552
Spiriva Respimat Tiotropium Bromide Brand 68 $60,988
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 46 $47,877
Breo Ellipta Fluticasone/Vilanterol Brand 43 $31,137
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 43 $30,011
Spiriva Handihaler Tiotropium Bromide Brand 27 $27,466
Albuterol Sulfate Hfa Albuterol Sulfate Brand 409 $16,215

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$20,320

Medicare's payments for the services billed

Medicare patients

287

Average age 72

Services billed

396

138 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
COPD 56%
Diabetes 44%
Ischemic heart disease 43%
Chronic kidney disease 36%
Depression 31%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$370 356 —
OFEV
$246 — —
NUCALA
$225 23 —
Prolastin-C Liquid
$222 13 —
Sunosi
$211 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

737 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record